ReviewHuman vaccines & immunotherapeutics2013
Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials.Drugs & aging · 2015Pooled it
- Article
- Dual impact of squalene-adjuvanted influenza vaccine on immunity and glucose homeostasis in obese mice.Scientific reports · 2026Article
- Recent developments of vaccines for older adults: Adjuvants and beyond.Human vaccines & immunotherapeutics · 2025Review
- Assessment of Cross-Reactive Neutralizing Antibodies Induction Against H5N1 Clade 2.3.4.4b by Prior Seasonal Influenza Immunization in Retail Workers.Open forum infectious diseases · 2025Article
- Article
- Effectiveness of influenza vaccine among the population in Chongqing, China, 2018-2022: A test negative design-based evaluation.Human vaccines & immunotherapeutics · 2024Observational
- Article
- Article
- Mechanism of activation of porcine dendritic cells by an α-D-glucan nanoparticle adjuvant and a nanoparticle/poly(I:C) combination adjuvant.Frontiers in immunology · 2022Article
- A New Nano Adjuvant of PF3 Used for an Enhanced Hepatitis B Vaccine.Frontiers in bioengineering and biotechnology · 2022Article
- Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.Immunity & ageing : I & A · 2021Review
- Broadly Protective CD8Journal of virology · 2021Article
- Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.Frontiers in immunology · 2020Review
- Article
- Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature.Human vaccines & immunotherapeutics · 2018Review
- AS03- and MF59-Adjuvanted Influenza Vaccines in Children.Frontiers in immunology · 2017Review
- Article
- A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.Infectious diseases and therapy · 2015Article
- Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains.Immunity & ageing : I & A · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigenic drift, the evolutionary mechanism of influenza viruses, results in an increased susceptibility of vaccinated subjects against circulating viruses. New vaccines able to grant a broader and cross-reactive immune response against drifted influenza variants are needed. Several strategies were explored to enhance the immunogenicity of plain vaccines: adjuvants, carriers and intradermal administration of influenza vaccine emerge as a promising options. To evaluate the ability of a MF59-adjuvanted and intradermal influenza vaccine to elicit an effective antibody response against circulating viruses presenting antigenic patterns different from those of the vaccine strains, we compared antibody responses elicited by "implemented" vaccines and conventional intramuscular trivalent inactivated vaccine against heterologous circulating influenza A viruses. Different studies, simulating different epidemiological pictures produced by the natural antigenic drift of seasonal influenza viruses, highlighted the superior cross-reactivity of the antibodies elicited by MF59 and intradermal vaccines, compared with subunit or split vaccine against heterologous viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.